← All trials
NCT04976153
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2021
- Primary completion
- Oct 31, 2023
- Completion date
- Feb 28, 2024
- First posted
- Jul 26, 2021
- Last posted
- Jul 26, 2021
- Enrollment
- 290
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Innovacell Biotechnologie AGLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.